key: cord-0876103-w5rc9lo3 authors: Schuit, E.; Venekamp, R. P.; Hooft, L.; Veldhuijzen, I. K.; van den Bijllaardt, W.; Pas, S. D.; Zwart, V. F.; Lodder, E. B.; Hellwich, M.; Koppelman, M.; Molenkamp, R.; Wijers, C.; Vroom, I. H.; Smeets, L. C.; Nagel-Imming, C. R.; Han, W. G.; van den Hof, S.; Kluytmans, J. A.; van de Wijgert, J. H.; Moons, K. G. title: Accuracy of COVID-19 self-tests with unsupervised nasal or nasal plus oropharyngeal self-sampling in symptomatic individuals in the Omicron period date: 2022-03-24 journal: nan DOI: 10.1101/2022.03.24.22272891 sha: 4ffeeaf6fab15963923452448b706846186d1dbe doc_id: 876103 cord_uid: w5rc9lo3 Background Performances of rapid antigen diagnostic tests (Ag-RDTs) with nasal self-sampling, and oropharyngeal plus nasal (OP-N) self-sampling, in the Omicron period are unknown. Methods Prospective diagnostic accuracy study among 6,497 symptomatic individuals aged [≥]16 years presenting for SARS-CoV-2 testing at three test-sites. Participants were sampled for RT-PCR (reference test) and received one Ag-RDT to perform unsupervised with either nasal self-sampling (during the emergence of Omicron, and after Omicron share was >90%, phase-1) or with OP-N self-sampling (in a subsequent phase-2; Omicron share >99%). The evaluated tests were Acon Flowflex (Flowflex; phase-1 only), MP Biomedicals (MPBio), and Siemens-Healthineers Clinitest (Clinitest). Findings During phase-1, 45% of Flowflex, 29% of MPBio, and 35% of Clinitest participants were confirmatory testers (previously tested positive by a self-test at own initiative). Overall sensitivities with nasal self-sampling were 79.0% (95% CI: 74.7-82.8%) for Flowflex, 69.9% (65.1-74.4%) for MPBio, and 70.2% (65.6-74.5%) for Clinitest. Sensitivities were substantially higher in confirmatory testers (93.6%, 83.6%, and 85.7%, respectively) than in those who tested for other reasons (52.4%, 51.5%, and 49.5%, respectively). Sensitivities decreased by 6.1 (p=0.16 by Chi-square test), 7.0 (p=0.60), and 12.8 (p=0.025) percentage points, respectively, when transitioning from 29% to >95% Omicron. During phase-2, 53% of MPBio, and 44% of Clinitest participants were confirmatory testers. Overall sensitivities with OP-N self-sampling were 83.0% (78.8%-86.7%) for MPBio and 77.3% (72.9%-81.2%) for Clinitest. Comparing OP-N to nasal sampling, sensitivities were slightly higher in confirmatory testers (87.4% and 86.1%, respectively), and substantially higher in those testing for other reasons (69.3% and 59.9%, respectively). Interpretation Sensitivities of three Ag-RDTs with nasal self-sampling decreased during Omicron emergence but was only statistically significant for Clinitest. Sensitivities were substantially influenced by the proportion of confirmatory testers. Addition of oropharyngeal to nasal self-sampling improved sensitivities of MPBio and Clinitest. Funding Dutch Ministry of Health, Welfare, and Sport. oropharyngeal to nasal self-sampling yields higher diagnostic accuracies. This large prospective diagnostic test accuracy study was embedded within the Dutch public testing 1 4 5 infrastructure. Testing is always by RT-PCR, free-of-charge, but only available for government-approved test 1 4 6 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 24, 2022. 7 indications. During the study, 21 December 2021 to 10 February 2021, these were: having (i) any symptom of 1 4 7 potential SARS-CoV-2 infection; (ii) been identified as close contact of a SARS-CoV-2 index case; (iii) tested 1 4 8 positive on any commercially available Ag-RDT after self-sampling at own initiative (confirmatory testers); or 1 4 9 1 9 8 Primary outcomes were diagnostic accuracy (sensitivity, specificity, positive and negative predictive values with 1 9 9 corresponding 95% confidence intervals [95% CI]) of each Ag-RDT either with nasal or with OP-N self-2 0 0 sampling, and RT-PCR testing as reference. Secondary outcomes were diagnostic accuracies stratified by reason 2 0 1 for testing (confirmatory testing after a positive self-test at one's own initiative, type of symptoms, close contact, 2 0 2 or other reason), COVID-19 vaccination status (no vaccination or vaccinated once, twice, or thrice), having had 2 0 3 prior SARS-CoV-2 infection, gender, and age (16-40, >40 years). Also, we assessed whether performance of the three Ag-RDTs with nasal self-sampling changed over time 2 0 5 during emergence of Omicron, by analysing the Ag-RDTs' sensitivities and specificities per week. Weekly 2 0 6 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 24, 2022. ; 9 intervals were chosen because the share of the Omicron variant in The Netherlands was assessed weekly in the 2 0 7 national pathogen surveillance. 16 Sensitivities in the first and last week were compared by Chi-square tests. All primary and secondary diagnostic accuracies were also determined after applying a viral load cut-off (≥5.2 2 0 9 log10 SARS-CoV-2 E-gene copies/mL). This was the viral load cut-off above which 95% of people with a 2 1 0 positive RT-PCR test had a positive virus culture based on previous work. 2 Furthermore, considering the large 2 1 1 influence of confirmatory testers in our study populations, all analyses were repeated stratified by confirmatory 2 1 2 testing (yes/no). Finally, self-reported user experiences with each Ag-RDT and self-reported numbers of infections that may have 2 1 4 been missed by baseline RT-PCR testing were assessed. We performed complete cases analysis because the number of individuals without RT-PCR test or Ag-RDT In our previous SD-Biosensor (Roche) SARS-CoV-2 nasal Ag-RDT self-testing study, we observed a sensitivity 2 2 0 of 79% in symptomatic participants. 7 For the present study, we conservatively assumed sensitivities of 70% for 2 2 1 all three Ag-RDTs irrespective of self-sampling method, with an error margin of 5%, type I error of 5% and 2 2 2 power of 80%. Hence, we aimed for 335 positive RT-PCR tests per Ag-RDT and per self-sampling method. Since Omicron was emerging at start of the study mid-December 2021, we extended the study to ensure accrual This study was funded by the Dutch Ministry of Health, Welfare, and Sport. The funder had no role in design; 2 2 8 collection, analysis, and interpretation of data; writing and decision to submit the paper for publication. Omicron transition phase are presented in Table S1 and for phases 1 and 2 in Table 1. 2 3 4 2 3 5 Overall Ag-RDT accuracies with nasal self-sampling in the Omicron period 2 3 6 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Ag-RDTs >93%, >96%, and >75%, respectively, in all analyses (Table 2 ). Supplementary Tables S5-S6 show all 2×2 tables. With some differences across the three Ag-RDTs, we found lower sensitivities in participants who had had a 2 5 2 previous SARS-CoV-2 infection, in women, and in those older than 40 (Table 2, Figure 2 ). Application of the 2 5 3 viral load cut-off resulted in higher sensitivities, but all stratification trends remained similar, except that 2 5 4 sensitivity differences by previous SARS-CoV-2 infection status were no longer significant for Flowflex ( Figure 2 5 5 S2). The largest differences in RT-PCR positivity percentages and Ag-RDTs performances were between 2 5 6 confirmatory testers and individuals who visited the test-site for other reasons ( Table S7 . Repeating all primary and secondary analyses in confirmatory and non-confirmatory testing participants 2 6 5 separately indicated no distinctly different trends in sensitivities across subgroups ( Figure S3 for nasal sampling 2 6 6 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 24, 2022. and Figure S4 for OP-N sampling). Differences across subgroups were less pronounced in the confirmatory 2 6 7 testers than in non-confirmatory testers, with much higher sensitivities among confirmatory testers in all strata. Clinitest (Chi-square test statistic 5.0; p-value=0.025). Specificities varied between 93.2% and 99.6% over time. Application of the viral load cut-off resulted in higher sensitivities but all trends over time remained similar 2 7 6 ( Figure 3 ). Stratification of the time trend analysis by reason for testing revealed that these time trends were similar but 2 7 8 more pronounced in non-confirmatory testers than in confirmatory testers, although confidence intervals are 2 7 9 wide ( Figure S5 ). showed overall sensitivities ranging from 70% to 79%, increasing to 77% to 85% when a viral load cut-off was 2 8 8 applied, for unsupervised nasal self-sampling during a period in which Omicron was dominant. Emergence of 2 8 9 Omicron was associated with a 6 to 13 percentage points decline in overall Ag-RDTs' sensitivities when 2 9 0 combined with nasal self-sampling, although this trend was only significant for Clinitest. The overall 2 9 1 sensitivities of the MPBio and Clinitest Ag-RDTs increased from 70% to 83% and 70% to 77%, respectively, 2 9 2 when combined with OP-N self-sampling instead of nasal self-sampling only. All above-mentioned sensitivities 2 9 3 were substantially higher in confirmatory testers than in those who visited test-sites for other reasons. Our pre-Omicron studies, and when less than 5% of participants were confirmatory testers, found sensitivities of 2 9 6 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 24, 2022. ; 12 72-83% for three different Ag-RDTs when performed by trained professionals, and 78.5% for the SD Biosensor 2 9 7 Ag-RDT when performed with unsupervised self-sampling from the nose. 7, 18, 19 The sensitivities that we found in 2 9 8 the first week of the current study, when Delta was still highly dominant, were similar (Flowflex 87%, MPBio 2 9 9 80%, and Clinitest 83%), although the percentage of confirmatory testers in this study was much higher (21%-3 0 0 24%). However, sensitivities declined to 80%, 70%, and 70%, respectively, in the Omicron period. Recent The largest differences in RT-PCR positivity percentages and Ag-RDTs' performance were between 3 1 7 confirmatory testers and individuals who attended the test-sites for other reasons. As expected, RT-PCR 3 1 8 positivity percentages were close to 100% in the confirmatory testers and substantially lower (30% to 43%) in 3 1 9 the 'other reasons' group. This agreed with test positivity percentages observed in national surveillance during 3 2 0 the study. Logically, a higher proportion of confirmatory testers (93-95%) than other testers (76-77%) had viral 3 2 1 loads above the used viral-load cut-off. Adding oropharyngeal to nasal sampling had a larger benefit in the other 3 2 2 reasons group (10-18% increase in sensitivity) than in the confirmatory testers group (<1-4%) because the 3 2 3 sensitivities were already very high in the latter group. We found trends towards lower sensitivities in participants who had a previous SARS-CoV-2 infection (60-67%) 3 2 6 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 24, 2022. ; https://doi.org/10.1101/2022.03.24.22272891 doi: medRxiv preprint 13 compared to those who had not (72-83%), with non-overlapping confidence intervals for Flowflex with nasal 3 2 7 self-sampling only. This trend was absent for MPBio with OP-N sampling. These findings should be interpreted 3 2 8 with caution due to the larger uncertainty around these subgroup specific accuracy estimates. However, we 3 2 9 observed similar trends for the BD-Veritor and SD-Biosensor Ag-RDTs with either professional or self-sampling 3 3 0 in two previous studies. 5, 7 The lower sensitivities of Ag-RDTs in individuals with a prior infection may be device. These effects might be test device-specific given the variability in the performance across the three AG-3 3 6 RDTs. 5 We also found trends towards slightly higher sensitivities in participants who never received a COVID-3 3 7 19 vaccination for the MPBio and Clinitest Ag-RDTs with nasal self-sampling, but all confidence intervals 3 3 8 overlapped with those who were vaccinated 1, 2 or 3 times and no differential impact was observed when Our study is the only Ag-RDT diagnostic accuracy study thus far that was conducted during the emergence of 3 4 3 Omicron, and that compared Ag-RDTs' performances with nasal self-sampling versus combined OP-N self-3 4 4 sampling. Additional strengths include the large numbers of participants recruited at multiple test-sites, the low 3 4 5 percentage of missing values, reference test sampling and Ag-RDT self-testing within a few hours, unsupervised 3 4 6 self-testing conform the real-world context of self-testing, blinding of participants for the reference test result, 3 4 7 blinding of laboratory staff for the Ag-RDT result, and the use of a viral load cut-off. Our study also has some limitations. First, the sample size calculation was based on the primary analysis and 3 4 9 diagnostic accuracy parameters are by definition less precise for stratified and weekly analyses. Second, we did 3 5 0 not determine the virus lineage in individual samples but relied on the national pathogen surveillance data to 3 5 1 estimate the weekly Omicron variant prevalence. 16 This surveillance system includes approximately 2,000 3 5 2 random samples from positive samples across the country on a weekly basis. Since regional variations in the 3 5 3 Netherlands are very small (data not shown), we are confident that Omicron's share was over 90% in all test-3 5 4 sites from 12 January 2022 onwards. Third, the viral load cut-off that we used was the cut-off above which 95% . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) We found that Ag-RDT performance with nasal self-sampling declined during the period that Omicron emerged. We also showed that Ag-RDT performance can be improved by adding oropharyngeal to nasal self-sampling. Therefore, after proper evaluation, Ag-RDT manufacturers may consider extending their instructions for use to self-test, individuals would be allowed to go to work or school. Our data show that this does reduce but not 3 6 9 minimize transmission risks because of the likelihood of false-negative Ag-RDT results. As per national policy, 3 7 0 we recommend that persons who test negative by self-test adhere to the general preventive measures such as 3 7 1 applying hand hygiene, ensure indoor ventilation, and wearing mouth-nose masks in crowed places. In case of a 3 7 2 positive self-test, self-isolation is required but confirmatory testing seems unnecessary in most situations if the 3 7 3 infection pressure is high. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 24, 2022. ; Klein . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 24, 2022. ; https://doi.org/10.1101/2022.03.24.22272891 doi: medRxiv preprint # Individuals could report more than one reason for testing, or more than one symptom, respectively. Participants were asked separately 4 4 5 whether they had symptoms on the day of study participation. All participants reported symptoms but only 60-65% reported having 4 4 6 symptoms as a reason for testing. $ Percentage calculated as proportion of those vaccinated, or those that had previous experience in performing a self-test, respectively. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 24, 2022. ; . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Test; MPBio = the MP Biomedicals Rapid SARS-CoV-2 Antigen Test Card; Clinitest = the Siemens- Healthineers CLINITEST Rapid COVID-19 Antigen Test. "Ag-RDT inconclusive" is a combination of Ag- RDTs that showed no control line, test tubes that were dropped, an Ag-RDTs that provided a result participants 4 6 5 had difficulties to interpret (e.g., very light line at the "T"). . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Clinitest, oropharyngeal−nasal sampling . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 24, 2022. ; https://doi.org/10.1101/2022.03.24.22272891 doi: medRxiv preprint 2021 − week 51 2021 − week 52 2022 − week 1 2022 − week 2 2022 − week 3 2022 − week 4 2022 − week 5 Week Sensitivity (dot) and Specificity (triangle We thank the participants, and study staff at the participating public health service test-sites, participating Flowflex inconclusive n=6No RT-PCR n=0 RT-PCR impossible to assess n=0Included in analysis with Flowflex and RT-PCR test result available n=620Excluded from analysis n=6 Clinitest n=740Clinitest negative n=424Clinitest positive n=303Clinitest inconclusive n=13RT-PCR n=423RT-PCR n=303 No RT-PCR n=0 RT-PCR impossible to assess n=1No RT-PCR n=0 RT-PCR impossible to assess n=0No RT-PCR n=0 RT-PCR impossible to assess n=0 Excluded from analysis n=13 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 24, 2022. Clinitest at viral load cut−off . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 24, 2022. ; https://doi.org/10.1101/2022.03.24.22272891 doi: medRxiv preprint